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helse-bergen.noAbstractPrimary hypomagnesemia with secondary hypocalcemia (HSH) is an autosomal recessive
disorder characterized by neuromuscular symptoms in infancy due to extremely low levels of
serum magnesium and moderate to severe hypocalcemia. Homozygous mutations in the
magnesium transporter gene transient receptor potential cation channel member 6 (TRPM6)
cause the disease. HSH can be misdiagnosed as primary hypoparathyroidism. The aim of this
study was to describe the genetic, clinical and biochemical features of patients clinically
diagnosed with HSH in a Norwegian cohort. Five patients in four families with clinical
features of HSH were identified, including one during a national survey of hypopara-
thyroidism. The clinical history of the patients and their families were reviewed and gene
analyses of TRPM6 performed. Four of five patients presented with generalized seizures in
infancy and extremely low levels of serum magnesium accompanied by moderate
hypocalcemia. Two of the patients had an older sibling who died in infancy. Four novel
mutations and one large deletion in TRPM6 were identified. In one patient two linked
homozygous mutations were located in exon 22 (p.F978L) and exon 23 (p.G1042V). Two
families had an identical mutation in exon 25 (p.E1155X). The fourth patient had a missense
mutation in exon 4 (p.H61N) combined with a large deletion in the C-terminal end of the
gene. HSH is a potentially lethal condition that can be misdiagnosed as primary
hypoparathyroidism. The diagnosis is easily made if serum magnesium is measured. When
treated appropriately with high doses of oral magnesium supplementation, severe
hypomagnesemia is uncommon and the long-term prognosis seems to be good.Key Words
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(2015) 4, 215–222IntroductionPrimary hypoparathyroidism is a rare condition with
multiple aetiologies, in adults most commonly caused by
damage to the parathyroid glands by surgery or radiation,
whereas autoimmune and genetic causes dominate in
children. Hypoparathyroidism can be isolated or can beone component of a syndrome like DiGeorge syndrome,
autoimmune polyglandular syndrome type 1 and other
rarer syndromes. Transient hypocalcemia due to the relative
resistance to parathyroid hormone (PTH) of the immature
neonatal kidney can also be encountered in infancy.sed under a Creative Commons
Commercial 4.0 International License.
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2–8 4 :216Hypomagnesemia blocks the release of PTH and
probably also decreases the sensitivity to circulating PTH
in target organs and thereby causes a biochemical picture
identical to primary hypoparathyroidism (1). Hypomag-
nesemia is usually caused by malnutrition or medication
such as diuretics, proton pump inhibitors, cetuximab
(epidermal growth factor (EGF) receptor inhibitor used for
colon cancer), certain antibiotics and immunosuppres-
sives. In rare cases, hypomagnesemia is hereditary (2, 3),
either isolated or combined with other electrolytes
disturbances like Bartter’s and Gitelman’s syndromes.
Over the last decades several genetic forms of hypomag-
nesemia have been identified, including mutations in
transient receptor potential cation channel member 6
(TRPM6), claudin 16 and 19, cyclin M2 (CNNM2) and the
EGF. For review, see (4).
Primary hypomagnesemia with secondary hypocalce-
mia (HSH) is an autosomal recessive disease characterized
by reduced intestinal absorption and renal reabsorption of
magnesium (5). HSH is the only known hereditary cause of
hypomagnesemia characterized by intestinal magnesium
wasting, first described by Paunier et al. (6). The causative
gene was later identified as TRPM6 (7, 8). TRPM6 is a cation
channel that shows a higher affinity to magnesium than
calcium (9, 10), expressed mainly in the intestinal
epithelium and nephrons (7). It is responsible for active
transcellular magnesium absorption in the intestine and
active reabsorption in the kidneys, a key player to keep
magnesium levels in the physiological range (11). Only at
relatively high magnesium intake does passive absorption
take place, which explains why high oral magnesium
intake can partially compensate for the defective active
absorption (7, 12).
HSH typically presents with generalized seizures or
increased neuromuscular excitability such as muscle
spasms or tetany during infancy (12, 13), but milder and
later presentations have been reported (14, 15, 16). HSH is
sometimes misdiagnosed as primary hypoparathyroidism,
due to the initial presenting symptoms of hypocalcemia
and concomitant low or inappropriate normal PTH (14).
A characteristic feature of the condition is an extremely
low level of serum magnesium, in most cases below
0.4 mmol/l, and usually accompanied by moderate hypo-
calcemia (13). The clinical symptoms of hypomagnesemia
are not easily distinguished from the symptoms of
hypocalcemia. Incorrect or delayed diagnosis and/or
treatment can lead to fatal convulsions and chronic
irreversible neurological complications (13, 17). Affected
patients require lifelong replacement with high oral doses
of magnesium. Here, we report the clinical and genetichttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0066
 2015 The authors
Published by Bioscientifica Ltdcharacteristics of five patients in four families diagnosed
in infancy with hypocalcemia and hypomagnesemia.Subjects and methods
Patients and design
In a survey of Norwegian patients with hypoparathyroidism
(Astor MC, Løva˚s K & Husebye ES, unpublished obser-
vations), one patient (F1.1) was identified through a search
in electronic hospital registries using the International
Classification of diseases (ICD) 10 code E83.5 (disorders of
calcium metabolism). Review of her medical record revealed
functional hypoparathyroidism due to hypomagnesemia as
the underlying cause. The other families described were
subsequently identified by members of the national study
group for hypoparathyroidism using the following criteria:
chronic hypomagnesemia from first year of life combined
with low serum calcium that was correctable upon
administration of magnesium salts; high faecal mag-
nesium in spite of hypomagnesemia. All the participants
or their guardians gave written informed consent. The
Ethics Committee of Western Norway approved the study.
Three of the patients (F2.1, F3.1, F4.1) previously
described with suspected HSH (18, 19, 20) were re-eval-
uated leading to the identification of the fifth patient
(F3.2) (Fig. 1 and Table 1). All patients and families were
Caucasian. Consanguinity was present in family 3, where
the index patient’s (F3.2) father and maternal grand-
mother were fourth cousins (not shown in Fig. 1).Biochemical analyses and calculation of magnesium
excretion
Urine magnesium–creatinine ratio and serum magnesium
were analysed using Modular P from Roche Diagnostics
at the laboratory for Clinical Chemistry at Haukeland
University Hospital. All other biochemical results were
obtained from the patients’ records, including calculation
of faecal and urine magnesium excretion, measured by
various methods; three of the patients (F2.1, F3.1 and F4.1)
went through comprehensive absorption studies using
radioactive magnesium (18, 19, 20), F1.1 had daily intake
and faecal and urinary excretion measured on three
consecutive days, whereas F3.2 had 24-h urine magnesium
estimated. PTH values were taken from historical records
and measured by various methods. In the evaluation of
F2.1, F3.1 and F4.1, a C-terminal-specific RIA (21) was
used. In all but one case (F3.2) these were first-generation
PTH assays and thereby of limited clinical importance.This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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Figure 1
Families with primary hypomagnesemia with secondary hypocalcemia.
Mutation statuses are shown for those family members where DNA was
available for testing; affected individuals are shown with filled symbols.
The identified mutation(s) and normal alleles (WT) are indicated beneath
the symbols for all tested individuals. Deceased individuals are marked by
a diagonal line.
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Sequencing of the whole coding region of the TRPM6 gene
was performed at the Laboratory for Molecular Diagnostics,
Centre for Nephrology and Metabolic Disorders (Weiss-
wasse, Germany), by Dr.med. Mato Nagel. Family members
were screened for the family mutation by standard Sanger
sequencing. Genomic DNA was extracted from whole blood
by the QIAamp DNA Blood mini kit from Qiagen following
the manufacturer’s protocol. Copy number variation
analysis was performed using a duplex real-time PCR assay
in which the number of copies of the TRPM6 gene was
compared to the copy number of an internal standard gene
(RNaseP from Applied Biosystem). The assay for copy
number variation was performed for five different sites of
the gene (intron 3 and exon 4, 20, 30 and 39). Primers,
probes and assay conditions are available upon request.Results
Clinical presentation
F1.1 presented with seizures during an episode with
fever at the age of 9 months, considered as febrile con-
vulsions. After a second episode, severe hypomagnesemiahttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0066
 2015 The authors
Published by Bioscientifica Ltd(0.16 mmol/l, reference range 0.71–0.94) and hypo-
calcemia (1.30 mmol/l, reference range 2.20–2.55) were
discovered (Table 1). Treatment with both intravenous
calcium and magnesium salts were given and electrolytes
normalized.
F2.1 had symptoms of generalized seizures from the
age of 6 weeks. Clinical examination revealed muscular
hyperirritability, positive Chvostek’s sign and carpopedal
spasms. He had moderately low serum calcium at
1.90 mmol/l accompanied by low serum magnesium at
0.25 mmol/l. Magnesium was given intravenously, which
resulted in normalization of both calcium and magnesium
levels. No further seizures were noted. An older brother
had died at 7 weeks of age due to persistent hypocalcemic
seizures resistant to calcium and vitamin D therapy,
indicating HSH as the cause of death. Serum magnesium
was not measured, and magnesium salts were not given.
F3.1 was admitted to hospital at the age of 4 weeks
with stiffness and opisthotonus. He received treatment
with anticonvulsants, which resulted in temporary
improvement. However, symptoms recurred and hypo-
magnesemia and hypocalcemia was then discovered. He
was successfully treated with intravenous magnesium, and
later oral replacement. An older brother had died at
8 weeks old due to ‘muscular weakness’ (further details
on his medical history were not found). F3.2 had
twitching of extremities and regurgitation from birth.
Serum magnesium was measured at the age of 10 days, the
HSH diagnosis made and properly treated, and he has
never experienced serious hypomagnesemia symptoms.
F4.1 had repeated tetanic convulsions at the age of
4 weeks. On admission serum calcium was 1.85 mmol/l,
but calcium infusions neither relieved symptoms nor
increased serum calcium levels; on the contrary, calcium
gradually declined to a minimum of 1.35 mmol/l. After
discovering low serum magnesium of 0.25 mmol/l, paren-
teral magnesium therapy was given with normalization of
serum calcium, near normalization of magnesium and
complete disappearance of tetany. After the diagnosis was
properly made, the patient has received continuous oral
magnesium supplementation. In the first year of life he
had two further episodes of seizures at the age of 6 and 10
months, the last of which appeared during febrile illness.Treatment and complications
All the patients were treated with oral magnesium
hydroxide, on average 19 mg/kg per day (range 10–
38 mg/kg per day). Dose increments were limited by
diarrhoea, and serum magnesium levels were constantlyThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Table 1 Clinical and biochemical characteristics of patients with HSH. Patient F2.1, F3.1 and F4.1 were clinically described in former
reports (18, 19, 20).
Patient F1.1 F2.1 F3.1 F3.2 F4.1
Age (years) 26 46 44 10 47
Gender F M M M M
Clinical and laboratory data at presentation
Age 9 months 3 weeks 4 weeks 10 days 4 weeks
Presentation Seizures Seizures Stiffness and
opisthotonus
Twitching of
extremities
Seizures
S-Mg (mmol/l) ref. range 0.71–0.94 0.16 0.25 NA 0.23 0.25
S-Ca (mmol/l) ref. range 2.20–2.55 1.37 1.90 NA 2.55 1.35
Faecal Mg-excretion (% of oral intake)a Increaseda 91% 82% NA 88%
Urinary Mg-excretion
% of absorbed oral intakeb 4% 7% NA – 2%
mmol/mol creatininec – – – 3.9 –
With stable oral magnesium supplementation
Daily oral Mg supplementation
(mmol/kg per day)d
0.8–1.0 0.5 0.4 0.5 1.6
Side effects of oral Mg Diarrhea Diarrhea Diarrhea None None
Serum-Mg (mmol/l) 0.5–0.6 0.6 0.6–0.7 0.7–0.8 0.7
Urine-Mg (mmol/mmol creatinine)
ref. range 0.20–0.50
0.03 0.12 0.04 0.23 0.58
Other medications Spironolactone None None None Immuno-
suppressants
TRPM6 mutations
Nucleotide exchange 1) c.2934COG
2) c.3125GOT
c.3463GOT c.3463GOT c.3463GOT 1) c.181COA
2) Deletion
Location 1) Exon 22
2) Exon 23
Exon 25 Exon 25 Exon 25 1) Exon 4
2) Between exon
30 and 39
Consequence protein 1) p.F978L
2) p.G1042V
p.E1155X p.E1155X p.E1155X 1) p.H61N
NA, not available.
aWith normal magnesium levels and intake, about 50–80% is excreted in feces. In hypomagnesemia or with low intake, the intestine is normally able to
reduce excretion to 10–20% (39, 40).
bIn magnesium depletion fractional renal excretion above 2% indicates renal wasting.
cRenal magnesium excretion (mmol/mol creatinine) should be below 2 in healthy infants.
dApproximately 0.15–0.20 mmol/kg per day in healthy people.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research M C Astor et al. Hypomagnesemia with
secondary hypocalcemia
4–8 4 :218in the subnormal range in all patients (Table 1). After
diagnosis and adequate treatment one of the patients had
an episode of seizures (F2.1) when not adhering to
magnesium supplementation. F1.1 was hospitalized at 21
years of age because of dysarthria, lethargy, vomiting,
headache and paraesthesia of her face and hands, but
without convulsions. Physical examination revealed
general muscle weakness and dysarthria, but was other-
wise normal. Biochemical tests revealed serum magnesium
at 0.40 mmol/l and albumin-corrected calcium at
1.64 mmol/l. Corrections of the electrolyte disturbances
with intravenous magnesium salt resulted in rapid clinical
improvement. On discharge she reinstated her usual oral
magnesium supplementation, which yielded serum mag-
nesium levels at 0.2–0.6 mmol/l, with persistent symp-
toms of lethargy and frequent need of intravenoushttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0066
 2015 The authors
Published by Bioscientifica Ltdmagnesium infusions. After adding 50 mg spironolactone,
the magnesium levels have been stable in the subnormal
range with a less frequent need for intravenous mag-
nesium. Patient F4.1 died during the study period at the
age of 47 of causes unrelated to HSH.Biochemical phenotype
Study of the magnesium balance in childhood (F1.1, F2.1,
F3.1 and F4.1) demonstrated that faecal magnesium
excretion was high despite of hypomagnesemia
(Table 1). Testing during childhood also showed that
urinary magnesium excretion was low, but nevertheless
inappropriately high relative to the hypomagnesemia.
Patient F3.2 had a low PTH of 0.1 pmol/l (reference range
1.3–6.8) at the time of diagnosis. None of the otherThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research M C Astor et al. Hypomagnesemia with
secondary hypocalcemia
5–8 4 :219patients had PTH measured at the time of diagnosis, but
PTH values during stable oral magnesium supple-
mentation (F1.1) and during clinical testing without
magnesium supplementation for 5 days to 2 weeks (F2.1,
F3.1, F4.1) (18) were within the normal reference range in
all the other patients. Serum magnesium levels in both
heterozygous gene carriers and unaffected family members
were normal (0.81–0.90 mmol/l).Gene analysis of TRPM6
All patients exhibited mutations in the TRPM6 gene
(Fig. 2). Four novel mutations and one deletion were
identified (Table 1). F1.1 had two novel missense
mutations in exons 22 and 23 respectively and was
homozygous for both mutations. Copy number analysis
revealed two copies of the gene throughout the whole
sequence. The parents and the tested sibling were
heterozygous for the same mutations, all of them with
normal electrolytes. The mutation in exon 22 (F978L) is
located in one of the transmembrane segments of the
TRPM6 protein, whereas the mutation in exon 23
(G1042V) is located at the putative pore-forming region
of the protein. Members of families 2 and 3 harboured
a homozygous nonsense mutation (p.E1155X) in exon 25
just proximal of the a-kinase domain giving a truncatedFigure 2
Schematic illustration of the TRPM6 gene with the novel mutations and the
deletion indicated. Mutations in exon 4, 22 and 23 are missense mutations
located in conserved residues. The mutation in exon 25 is a non-sense
mutation. The mutation in exon 4 and the deletion at the C-terminal end is
http://www.endocrineconnections.org
DOI: 10.1530/EC-15-0066
 2015 The authors
Published by Bioscientifica Ltdprotein. In family 4, we first identified a missense
mutation in a highly conserved histidine (p.H61N) in
exon 4. Subsequent copy number analysis revealed a
deletion in the other allele, consistent with a compound
heterozygous genotype. The mother carried the deletion,
located at the C-terminal end between exons 30 and 39
(two copies in intron 3, exons 3, 20 and 30, but only
1 copy in exon 39; boundaries not further localized).Discussion
We here describe five patients in four families with severe
childhood hypomagnesemia and HSH confirmed by
mutational analyses of the TRPM6 gene. The index
patients in all families presented in infancy with seizures
and/or tetany, indicating hypocalcemia. Based on our
cohort, a very rough estimate yields a minimum preva-
lence of one per million in the Norwegian population.
One may speculate if the true prevalence is higher due to
undiagnosed cases.
HSH is inherited in an autosomal recessive manner,
except in a family described by Walder in which only one
mutation was found, a C-to-T transition in exon 4 (R56X).
However, a large deletion could have been present as was
the situation in our family 4 and other cases reported in
the literature (7, 13). A few cases of late presentations ofa compound heterozygote mutation (patient F4.1). The horizontal bars
indicate the location of the mutations and the deletion, linked to the
relevant case(s).
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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identification of the causative gene. Whether these are
caused by mutations in TRPM6 is unclear. Heterozygous
mutation carriers are asymptomatic with normal serum
magnesium, in contrast to heterozygous mice, which have
mild hypomagnesemia (22, 23). Homozygous TRPM6K/K
mice exhibit a more severe phenotype than humans, with
increased embryonic lethality and induce a high mortality
rate for those who survive to term. As far as we know, F3.2
is the first described offspring of a patient with HSH.
TRPM6 are also expressed in the testicles, but the clinical
impact of the mutation on the male fertility is unknown.
The clinical presentation in our study was very similar
to previously described cases (12, 13) and demonstrates
the importance of early identification and treatment of
the disease. Dysarthria in the setting of HSH, seen also in
patient F1.1, has been reported earlier (13), and also in the
hypomagnesemia caused by renal failure (24). The typical
constellation with extreme hypomagnesemia combined
with moderate hypocalcemia was present in all but one
patient (F3.2) who had normal calcium levels at the time
of diagnosis only 10 days after birth. Faecal and urinary
magnesium excretion was high in those patients from
whom we had available results, as expected in HSH.
HSH patients are usually well managed on oral
magnesium supplementation without severe compli-
cations if they adhere to the treatment. Our patients
had average disease duration of over 40 years without
serious complications. One of the patients had an episode
of dysarthria – in our experience an atypical symptom in
hypomagnesemia – after a period of non-compliance, and
has needed regularly intravenous magnesium supple-
mentation in addition to high daily oral doses for several
years to overcome symptomatic hypomagnesemia. The
average daily magnesium dose used in the adult patients
was 1000 mg (15 mg/kg, corresponding to 0.6 mmol/kg)
similar to another report (0.93 mmol/kg) (13). Diarrhoea
is the main limiting factor for dosing. All the Norwegian
patients were treated with magnesium hydroxide, even if
studies indicate better absorption and fewer problems
with loose stools with magnesium chloride or magnesium
lactate (25). Treatment with spironolactone was effective
in increasing the serum magnesium in one of the
patients. High doses of spironolactone have been shown
to reduce magnesuria in Gitelman’s syndrome (26) and
control subjects, but studies on magnesium excretion
in response to low-dose spironolactone are sparse.
Conversely, there is ample documentation of the
magnesium-sparing effect of amiloride, which reduces
the magnesium excretion regardless of the cause ofhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0066
 2015 The authors
Published by Bioscientifica Ltdhypomagnesemia (27, 28, 29). A study by Murdoch
et al. (29) found that amiloride but not spironolactone
was associated with a dose-related increase in plasma
magnesium in thiazide treated patients.
Until now, 48 different pathogenic mutations in the
TRPM6 gene have been published (7, 8, 13, 30, 31, 32, 33,
34, 35, 36, 37) and about 70 cases with HSH have been
published worldwide. Mutations in TRPM6 are spread
throughout the whole gene, without clustering in any
specific domain (13). This is also reflected by the novel
mutations detected in the current study. The mutation in
exon 22, F978L, probably disrupts a membrane spanning
a-helix crucial for the TRPM6 channel activity, while the
mutation in exon 23, G1042V, might affect the compo-
sition of the ion pore itself. Both of the mutated amino
acids are conserved through evolution, indicating essen-
tial roles for proper function of the ion channel.
The mutation in exon 25, E155X, creates a premature
stop-codon, resulting in a truncated TRPM6 protein
without kinase activity. The H61N mutation, also a highly
conserved amino acid, is located in a poorly described
region of the TRPM6 protein, but it has been proposed that
the N-terminal intracellular domain of TRPM6 is crucial
for oligomerization (38).
In conclusion, HSH is a rare cause of hypomagnese-
mia, hypocalcemia and functional hypoparathyroidism,
illustrated here in four families with five novel gene
defects in TRPM6. An early diagnosis of HSH is crucial and
the possibility of TRPM6 mutations should be known to
both paediatricians and adult endocrinologists. As this
condition is clinically indistinguishable from hypocalce-
mia, the measurement of serum magnesium is mandatory
in the setting of hypocalcemia.Declaration of interest
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